PT - JOURNAL ARTICLE AU - Raghavan, Kadalraja AU - Sivakumar, Thanasekar AU - Bharatidasan, Sudhakar S AU - Srinivasan, Subramaniam AU - Dedeepiya, Vidyasagar Devaprasad AU - Ikewaki, Nobunao AU - Senthilkumar, Rajappa AU - Preethy, Senthilkumar AU - Abraham, Samuel JK TI - Efficacy of N-163 strain of <em>Aureobasidium pullulans</em>-produced beta-glucan in improving muscle strength and function in patients with Duchenne muscular dystrophy; Results of a 6-month non-randomised open-label linear clinical trial AID - 10.1101/2023.04.29.23289260 DP - 2023 Jan 01 TA - medRxiv PG - 2023.04.29.23289260 4099 - http://medrxiv.org/content/early/2023/05/02/2023.04.29.23289260.short 4100 - http://medrxiv.org/content/early/2023/05/02/2023.04.29.23289260.full AB - Duchenne muscular dystrophy (DMD) is a debilitating genetic disease that causes gradual muscle weakening and early mortality. After a 45-day clinical pilot study and a pre-clinical study in mdx mice demonstrating safety and efficacy, and anti-fibrotic and anti-inflammatory effects, respectively, of an Aureobasidium pullulans N-163 strain-produced B-1,3–1,6-glucan. We conducted this linear six-month clinical study to assess its efficacy. Twelve ambulatory and 12 non-ambulatory individuals with DMD were included; all received the N-163 strain of A.pullulans produed beta-glucan dietary supplement orally in addition to the standard treatment regimen, which included steroids. The Medical Research Council muscle score improved in 11 patients in the ambulatory group and in 8 patients in the non-ambulatory group. The six-minute walk test distance improved in nine patients, with a 29.5-meter average improvement. The North Star Ambulatory Assessment improved by 1 unit in three patients. This safe beta-glucan food supplement improved muscle function within 6 months. A comprehensive, multi-centric clinical research should be conducted for unravelling its potential as a disease-modifying drug adjuvant in DMD.Competing Interest StatementAuthor Samuel Abraham is a shareholder in GN Corporation, Japan which holds shares of Sophy Inc., Japan., the manufacturers of novel beta glucans using different strains of Aureobasidium pullulans; a board member in both the companies and also an applicant to several patents of relevance to these beta glucans.Clinical TrialCTRI/2022/05/042905Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was registered in Clinical trials registry of India, CTRI 2022 05 042905 and approved by the ethics committee of Saravana Multispeciality Hospital Institutional Ethics Committee, IndiaI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscriptDMDDuchenne muscular dystrophy6MWTSix-minute walk testNSAANorth Star Ambulatory AssessmentMRCMedical Research Council